Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

被引：2
|
作者：
Kienle, D. [1 ]
Winterhalder, R. [2 ]
Koeberle, D. [3 ]
Horber, D. [4 ]
Kueng, M. [5 ]
Saletti, P. [6 ]
Helbling, D. [7 ]
Bastian, S. [8 ]
Dietrich, D. [9 ]
Baertschi, D. [9 ]
Pilop, C. [9 ]
Von Moos, R. [8 ]
机构：
[1] Stadtspital Triemli, Haematol & Med Oncol, Zurich, Switzerland
[2] Kantonsspital Luzern, Med Oncol, Luzern, Switzerland
[3] Claraspital Basel, Oncol, Basel, Switzerland
[4] Kantonsspital St Gallen, Oncol Haematol, St Gallen, Switzerland
[5] HFR, Med Oncol, Fribourg, Switzerland
[6] Oncol Inst Southern Switzerland, Med Oncol, Bellinzona, Switzerland
[7] OnkoZentrum Klin Pk, Oncol, Zurich, Switzerland
[8] Kantonsspital Graubuenden, Oncol Haematol, Chur, Switzerland
[9] Swiss Grp Clin Canc Res, Coordinating Ctr, Bern, Switzerland
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30565-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1322
引用
收藏
页码：S194 / S195
页数：2
相关论文
共 50 条
  • [1] Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10
    Kienle, Dirk L.
    Dietrich, Daniel
    Ribi, Karin
    Wicki, Andreas
    Quagliata, Luca
    Winterhalder, Ralph C.
    Koeberle, Dieter
    Horber, Daniel
    Bastian, Sara
    Kueng, Marc
    Saletti, Piercarlo
    Helbling, Daniel
    Baertschi, Daniela
    Lugli, Alessandro
    Bernhard, Juerg
    Andrieu, Christiane
    von Moos, Roger
    JOURNAL OF GERIATRIC ONCOLOGY, 2019, 10 (02) : 304 - 310
  • [2] Maintenance treatment with capecitabine plus cetuximab after first-line standard fluorouracil-based chemotherapy plus cetuximab for patients with RAS wild-type advanced colorectal cancer.
    Yuan, Xianglin
    Zhao, Ben
    Qiu, Hong
    Zhang, Mingsheng
    Zou, Yanmei
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [3] Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
    Samalin, Emmanuelle
    Mazard, Thibault
    Assenat, Eric
    Rouyer, Magali
    de la Fouchardiere, Christelle
    Guimbaud, Rosine
    Smith, Denis
    Portales, Fabienne
    Ychou, Marc
    Adenis, Antoine
    Fiess, Catherine
    Lopez-Crapez, Evelyne
    Thezenas, Simon
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1375 - 1381
  • [4] Phase II trial of modified FOLIRI plus Panitumumab as first-line treatment in elderly patients with RAS wild-type metastatic colorectal cancer.
    Karampeazis, Athanasios
    Vamvakas, Lampros
    Kentepozidis, Nikolaos K.
    Kotsakis, Athanasios
    Kalbakis, Kostas
    Xynogalos, Spyros
    Sougklakos, Ioannis
    Emmanouilides, Christos E.
    Voutsina, Alexandra
    Hatzidaki, Dora
    Georgoulias, Vassilis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Results of a Phase II Trial of Cetuximab plus Capecitabine/Irinotecan as First-Line Therapy for Patients with Advanced and/or Metastatic Colorectal Cancer
    Cartwright, Thomas
    Kuefler, Paul
    Cohn, Allen
    Hyman, William
    Berger, Maury
    Richards, Donald
    Vukelja, Svetislava
    Nugent, John E.
    Ruxer, Robert L., Jr.
    Boehm, Kristi A.
    Asmar, Lina
    CLINICAL COLORECTAL CANCER, 2008, 7 (06) : 390 - 397
  • [6] First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study
    Mendez Mendez, Jose Carlos
    Salgado Fernandez, Mercedes
    de la Camara Gomez, Juan
    Pellon Augusto, Mari Luz
    Covela Rua, Marta
    Quintero Aldana, Guillermo
    Fernandez Montes, Ana
    Reboredo Lopez, Margarida
    Valladares Ayerbes, Manuel
    Jorge Fernandez, Monica
    Gonzalez Villarroel, Paula
    Romero Reinoso, Carlos
    Ramos Vazquez, Manuel
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (08) : 1263 - 1267
  • [7] Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer
    Giuliani, Jacopo
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1674 - 1676
  • [8] Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study
    Pinto, Carmine
    Orlandi, Armando
    Normanno, Nicola
    Maiello, Evaristo
    Calegari, Maria A.
    Antonuzzo, Lorenzo
    Bordonaro, Roberto
    Zampino, Maria G.
    Pini, Sara
    Bergamo, Francesca
    Tonini, Giuseppe
    Avallone, Antonio
    Latiano, Tiziana P.
    Rosati, Gerardo
    Cogoni, Alessio Aligi
    Ballestrero, Alberto
    Zaniboni, Alberto
    Roselli, Mario
    Tamberi, Stefano
    Barone, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1278 - 1287
  • [9] Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
    Yamaguchi, Kensei
    Ando, Masahiko
    Ooki, Akira
    Beier, Frank
    Guenther, Silke
    von Hohnhorst, Philipp
    Van Cutsem, Eric
    CLINICAL COLORECTAL CANCER, 2017, 16 (02) : E29 - E37
  • [10] Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial
    Kasper, Stefan
    Meiler, Johannes
    Knipp, Heike
    Hohler, Thomas
    Reimer, Peter
    Steinmetz, Tilman
    Berger, Winfried
    Linden, Gabriele
    Reis, Henning
    Markus, Peter
    Paul, Andreas
    Dechene, Alexander
    Schumacher, Brigitte
    Kostbade, Karina
    Virchow, Isabel
    Ting, Saskia
    Worm, Karl
    Schmid, Kurt W.
    Herold, Thomas
    Wiesweg, Marcel
    Schuler, Martin
    Trarbach, Tanja
    CLINICAL COLORECTAL CANCER, 2020, 19 (04) : 236 - +
12345